- Home
- DMAC vs DVS Comparison
DMAC vs DVS Comparison
Compare DMAC & DVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- DVS
- Stock Information
- Founded
- DMAC 2000
- DVS 2011
- Country
- DMAC United States
- DVS Canada
- Employees
- DMAC N/A
- DVS N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- DVS
- Sector
- DMAC Health Care
- DVS
- Exchange
- DMAC Nasdaq
- DVS Nasdaq
- Market Cap
- DMAC 310.1M
- DVS 362.6M
- IPO Year
- DMAC N/A
- DVS N/A
- Fundamental
- Price
- DMAC $6.96
- DVS $4.76
- Analyst Decision
- DMAC Strong Buy
- DVS
- Analyst Count
- DMAC 3
- DVS 0
- Target Price
- DMAC $12.33
- DVS N/A
- AVG Volume (30 Days)
- DMAC 343.5K
- DVS 915.8K
- Earning Date
- DMAC 11-12-2025
- DVS 11-23-2025
- Dividend Yield
- DMAC N/A
- DVS N/A
- EPS Growth
- DMAC N/A
- DVS N/A
- EPS
- DMAC N/A
- DVS N/A
- Revenue
- DMAC N/A
- DVS N/A
- Revenue This Year
- DMAC N/A
- DVS N/A
- Revenue Next Year
- DMAC N/A
- DVS N/A
- P/E Ratio
- DMAC N/A
- DVS N/A
- Revenue Growth
- DMAC N/A
- DVS N/A
- 52 Week Low
- DMAC $3.19
- DVS $2.48
- 52 Week High
- DMAC $7.49
- DVS $5.38
- Technical
- Relative Strength Index (RSI)
- DMAC 58.60
- DVS 58.97
- Support Level
- DMAC $6.75
- DVS $4.54
- Resistance Level
- DMAC $7.13
- DVS $5.13
- Average True Range (ATR)
- DMAC 0.28
- DVS 0.30
- MACD
- DMAC -0.06
- DVS -0.02
- Stochastic Oscillator
- DMAC 50.00
- DVS 52.77
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About DVS Dolly Varden Silver Corporation Common Shares
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.